Follow us:
  1. Home
  2. News
  3. Recalls

Bayshore Pharmaceuticals recalls Metformin Hydrochloride Extended-Release Tablets

The medication may be contaminated with a probable cancer-causer

Photo
Photo source: FDA
Bayshore Pharmaceuticals of Short Hills, N.J., is recalling one lot of Metformin Hydrochloride Extended-Release Tablets.

Testing of the medication, used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus, showed results for N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

NDMA is classified as a probable human carcinogen (a substance that could cause cancer). There are no reports of adverse events.

A list of the Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 750 mg lots being recalled may be found here.

What to do

Patients with questions may contact Bayshore Pharmaceuticals at (877) 372-6093.

Take a Medical Alert System Quiz

Get matched with an Accredited Partner

Share your comments